KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inovio Pharmaceuticals (INO) Treasury Shares (2016 - 2025)

Inovio Pharmaceuticals (INO) has disclosed Treasury Shares for 11 consecutive years, with $724941.0 as the latest value for Q4 2025.

  • Quarterly Treasury Shares rose 114.54% to $724941.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $724941.0 through Dec 2025, up 114.54% year-over-year, with the annual reading at $724941.0 for FY2025, 114.54% up from the prior year.
  • Treasury Shares hit $724941.0 in Q4 2025 for Inovio Pharmaceuticals, up from $669226.0 in the prior quarter.
  • In the past five years, Treasury Shares ranged from a high of $3.5 million in Q1 2022 to a low of $83800.0 in Q1 2025.
  • Historically, Treasury Shares has averaged $985837.8 across 5 years, with a median of $243879.0 in 2022.
  • Biggest five-year swings in Treasury Shares: crashed 95.66% in 2023 and later skyrocketed 279.64% in 2025.
  • Year by year, Treasury Shares stood at $2.4 million in 2021, then plummeted by 91.3% to $212964.0 in 2022, then grew by 29.03% to $274794.0 in 2023, then grew by 22.97% to $337911.0 in 2024, then surged by 114.54% to $724941.0 in 2025.
  • Business Quant data shows Treasury Shares for INO at $724941.0 in Q4 2025, $669226.0 in Q3 2025, and $83800.0 in Q2 2025.